PUBLIC COMPANY
save$RAPPRapport Therapeutics, Inc.
$RAPP46.98+3.28%Boston, MA, USupdated 4h ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
- phase3Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
- phase2Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder
- phase2Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
- phase2A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 17, 26SELLThird Rock Ventures V, L.P.· 10% owner−$17.18M↗
- Apr 17, 26SELLYeleswaram Krishnaswamy· Chief Development Officer−$809K↗
- Apr 14, 26SELLYeleswaram Krishnaswamy· Chief Development Officer−$358K↗
- Apr 13, 26SELLYeleswaram Krishnaswamy· Chief Development Officer−$321K↗
- Apr 10, 26SELLYeleswaram Krishnaswamy· Chief Development Officer−$17K↗
- Apr 8, 26SELLYeleswaram Krishnaswamy· Chief Development Officer−$13K↗
- Mar 30, 26SELLGault Cheryl· Chief Operating Officer−$201K↗
- Mar 30, 26SELLGault Cheryl· Chief Operating Officer−$81K↗
- Mar 25, 26SELLYeleswaram Krishnaswamy· Chief Development Officer−$303K↗
- Mar 5, 26SELLGault Cheryl· Chief Operating Officer−$58K↗
- Feb 18, 26SELLCeesay Abraham· Chief Executive Officer−$103K↗
- Feb 18, 26SELLCeesay Abraham· Chief Executive Officer−$87K↗
- Feb 18, 26SELLCeesay Abraham· Chief Executive Officer−$68K↗
- Feb 18, 26SELLCeesay Abraham· Chief Executive Officer−$63K↗
- Feb 17, 26SELLBredt David· Chief Scientific Officer−$156K↗
- Feb 17, 26SELLBredt David· Chief Scientific Officer−$65K↗
- Feb 17, 26SELLBredt David· Chief Scientific Officer−$25K↗
routine RSU / option mechanics (2)
- Feb 19, 26option exerciseBredt David · Chief Scientific Officer6,000 sh
- Feb 19, 26option exerciseBredt David · Chief Scientific Officer6,000 sh
🐶 Hiring Signal
next earnings Nov 5, 2026
Where Rapport Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaCNS / Neuroscience 10
News
no news has mentioned this company yet
Data sources
last refreshed 28m ago
Found something off?
comments(0)
5-min edit window · permanent after that